id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-349010-n4s8dzgp	Al-Tawfiq, Jaffar A.	Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV)	2016-12-24		.txt	text/plain	4266	237	47	The Middle East respiratory syndrome coronavirus (MERS-CoV) emerged as an important virus in 2012 and since then has caused multiple outbreaks in hospitals especially in the Kingdom of Saudi Arabia and outside the Arabian Peninsula [1] [2] [3] . Based on analysis of SARS data, interferon-ribavirin combination was suggested as a possible therapeutic option for the treatment of MERS-CoV infections [5] . Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study Inhibition of Middle East respiratory syndrome coronavirus (MERS-CoV) infection by anti-CD26 monoclonal antibody Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol Towards the prophylactic and therapeutic use of human neutralizing monoclonal antibodies for Middle East respiratory syndrome coronavirus (MERS-CoV)	./cache/cord-349010-n4s8dzgp.txt	./txt/cord-349010-n4s8dzgp.txt